X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The net proceeds will be used to advance the development of MLR-1023 (tolimidone), a selective activator of the enzyme lyn kinase which increases phosphorylation of insulin substrate 1, being developed for the treatment of type 1 diabetes.
Lead Product(s): Tolimidone
Therapeutic Area: Endocrinology Product Name: MLR-1023
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ladenburg Thalmann
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 21, 2023
Details:
Under the agreement, Biodexa gain rights to develop and commercialize MLR-1023 (tolimidone), a selective activator of the enzyme lyn kinase and Phase II Ready Asset for Type 1 Diabetes.
Lead Product(s): Tolimidone
Therapeutic Area: Endocrinology Product Name: MLR-1023
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Biodexa Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 27, 2023
Details:
Adhera will license MLR-1023 (tolimidone) from Melior Pharma 1 for the purpose of developing a novel therapeutic for Type 1 diabetes. MLR-1023, a lyn kinase activator, which has shown exceptional clinical safety and tolerability in Phase 2a and Phase 2b Type 2 diabetes.
Lead Product(s): Tolimidone
Therapeutic Area: Endocrinology Product Name: MLR-102
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Melior Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 24, 2021
Details:
The planned Phase 2 study is intended to recruit 236 subjects who were recently diagnosed with COVID-19, have early symptoms, but are not hospitalized. Tolimidone will be taken as an orally administered pill once a day.
Lead Product(s): Tolimidone
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2021
Details:
The Phase 2 clinical trial is intended to test tolimidone in subjects who were recently diagnosed with COVID19, but are not hospitalized. Tolimidone is expected to mitigate the probability and severity of COVID-19 subjects developing severe lung complications.
Lead Product(s): Tolimidone
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Commonwealth of Pennsylvania’s COVID-19 Vaccines
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding September 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
